Epiomic Epidemiology Series: Mucopolysaccharidosis Type IV Forecast in 28 Major Markets 2018–2028

April 2018 | 88 pages | ID: E144EF9EBBBEN
Black Swan Analysis limited

Abstracts

Black Swan Analysis Epiomic Epidemiology Forecast Report on Mucopolysaccharidosis Type IV in 28 Major Markets

Mucopolysaccharidosis type IV (MPS IV), also known as Morquio syndrome, is an inherited autosomal recessive genetic disorder in which glycosaminoglycans (GAGs) are accumulated in lysosomes due to mutations that cause loss of function of an enzyme responsible for degrading GAGs. The disorder manifests with multiple skeletal defects and has two subtypes, MPS IVA and MPS IVB, differing in the mutated gene. MPS IV constitutes a burden to the patients and their families as the disease progresses and the patients develop mobility impairment, breathing problems and corneal clouding.

This report provides the current prevalent population for MPS IV across 28 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Belgium, Norway, Sweden, Denmark, Switzerland, Ireland, Portugal, Czech Republic, Russia, Turkey, Saudi Arabia, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, MPS IV patients grouped by disease subtype, history of surgical procedures and comorbidities have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities of MPS IV include:

• Recurrent upper respiratory tract infections
• Sleep apnoea
• Pulmonary hypertension
• Osteoporosis
• Inguinal hernia
• Hepatomegaly
• Dental caries
• Vision impairment
• Hearing impairment and loss
• Disturbances in urinary function

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world-class sources that deliver the most up-to-date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

Ability to quantify patient populations in global MPS IV market to target the development of future products, pricing strategies and launch plans.

Further insight into the prevalence of the subdivided types of MPS IV and identification of patient segments with high potential.

Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.

Better understanding of the impact of specific co-morbid conditions on the prevalent population of MPS IV patients.

Identification of MPS IV patient sub-populations that require treatment.

Better understanding of the specific markets that have the largest number of MPS IV patients.

Contents

INTRODUCTION

CAUSE OF THE DISEASE

RISK FACTORS & PREVENTION

DIAGNOSIS OF THE DISEASE

VARIATION BY GEOGRAPHY/ETHNICITY

DISEASE PROGNOSIS & CLINICAL COURSE

KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE

METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS

TOP-LINE PREVALENCE FOR MUCOPOLYSACCHARIDOSIS TYPE IV

FEATURES OF MUCOPOLYSACCHARIDOSIS TYPE IV PATIENTS

MPS IVA

HISTORY OF SURGICAL PROCEDURES IN MPS IVA PATIENTS

COMORBIDITIES OF MPS IVA PATIENTS

ABBREVIATIONS USED IN THE REPORT

OTHER BLACK SWAN SERVICES & SOLUTIONS

REPORTS & PUBLICATIONS

ONLINE EPIDEMIOLOGY DATABASES

ONLINE PHARMACEUTICAL PRICING DATABASE

REFERENCES

APPENDIX

List Of Tables

LIST OF TABLES AND FIGURES

Table 1. Overview of common clinical manifestations of MPS IVA
Table 2. Prevalence of MPS IV, total (000s)
Table 3. Prevalence of MPS IV, males (000s)
Table 4. Prevalence of MPS IV, females (000s)
Table 5. Patients with MPS IV by subtype, total (000s)
Table 6. Patients with MPS IVA by phenotype/severity, total (000s)
Table 7. MPS IVA patients with a history of surgical operation, total (000s)
Table 8. MPS IVA patients with a history of decompression / cervical fusion, total (000s)
Table 9. MPS IVA patients with a history of spine surgery, total (000s)
Table 10. MPS IVA patients with a history of hip surgery, total (000s)
Table 11. MPS IVA patients with a history of femur surgery, total (000s)
Table 12. MPS IVA patients with a history of knee surgery, total (000s)
Table 13. MPS IVA patients with a history of ankle fusion, total (000s)
Table 14. MPS IVA patients with hearing loss, total (000s)
Table 15. MPS IVA patients with abnormal gait, total (000s)
Table 16. MPS IVA patients with genu valgum, total (000s)
Table 17. MPS IVA patients with eye problems, total (000s)
Table 18. MPS IVA patients with a history of ear infections, total (000s)
Table 19. MPS IVA patients with a history of respiratory infections, total (000s)
Table 20. Abbreviations and acronyms used in the report
Table 21. USA prevalence of MPS IV by 5-yr age cohort, males (000s)
Table 22. USA prevalence of MPS IV by 5-yr age cohort, females (000s)
Table 23. Canada prevalence of MPS IV by 5-yr age cohort, males (000s)
Table 24. Canada prevalence of MPS IV by 5-yr age cohort, females (000s)
Table 25. France prevalence of MPS IV by 5-yr age cohort, males (000s)
Table 26. France prevalence of MPS IV by 5-yr age cohort, females (000s)
Table 27. Germany prevalence of MPS IV by 5-yr age cohort, males (000s)
Table 28. Germany prevalence of MPS IV by 5-yr age cohort, females (000s)
Table 29. Italy prevalence of MPS IV by 5-yr age cohort, males (000s)
Table 30. Italy prevalence of MPS IV by 5-yr age cohort, females (000s)
Table 31. Spain prevalence of MPS IV by 5-yr age cohort, males (000s)
Table 32. Spain prevalence of MPS IV by 5-yr age cohort, females (000s)
Table 33. UK prevalence of MPS IV by 5-yr age cohort, males (000s)
Table 34. UK prevalence of MPS IV by 5-yr age cohort, females (000s)
Table 35. Poland prevalence of MPS IV by 5-yr age cohort, males (000s)
Table 36. Poland prevalence of MPS IV by 5-yr age cohort, females (000s)
Table 37. Netherlands prevalence of MPS IV by 5-yr age cohort, males (000s)
Table 38. Netherlands prevalence of MPS IV by 5-yr age cohort, females (000s)
Table 39. Belgium prevalence of MPS IV by 5-yr age cohort, males (000s)
Table 40. Belgium prevalence of MPS IV by 5-yr age cohort, females (000s)
Table 41. Norway prevalence of MPS IV by 5-yr age cohort, males (000s)
Table 42. Norway prevalence of MPS IV by 5-yr age cohort, females (000s)
Table 43. Sweden prevalence of MPS IV by 5-yr age cohort, males (000s)
Table 44. Sweden prevalence of MPS IV by 5-yr age cohort, females (000s)
Table 45. Denmark prevalence of MPS IV by 5-yr age cohort, males (000s)
Table 46. Denmark prevalence of MPS IV by 5-yr age cohort, females (000s)
Table 47. Switzerland prevalence of MPS IV by 5-yr age cohort, males (000s)
Table 48. Switzerland prevalence of MPS IV by 5-yr age cohort, females (000s)
Table 49. Ireland prevalence of MPS IV by 5-yr age cohort, males (000s)
Table 50. Ireland prevalence of MPS IV by 5-yr age cohort, females (000s)
Table 51. Portugal prevalence of MPS IV by 5-yr age cohort, males (000s)
Table 52. Portugal prevalence of MPS IV by 5-yr age cohort, females (000s)
Table 53. Czech Republic prevalence of MPS IV by 5-yr age cohort, males (000s)
Table 54. Czech Republic prevalence of MPS IV by 5-yr age cohort, females (000s)
Table 55. Russia prevalence of MPS IV by 5-yr age cohort, males (000s)
Table 56. Russia prevalence of MPS IV by 5-yr age cohort, females (000s)
Table 57. Turkey prevalence of MPS IV by 5-yr age cohort, males (000s)
Table 58. Turkey prevalence of MPS IV by 5-yr age cohort, females (000s)
Table 59. Saudi Arabia prevalence of MPS IV by 5-yr age cohort, males (000s)
Table 60. Saudi Arabia prevalence of MPS IV by 5-yr age cohort, females (000s)
Table 61. Japan prevalence of MPS IV by 5-yr age cohort, males (000s)
Table 62. Japan prevalence of MPS IV by 5-yr age cohort, females (000s)
Table 63. China prevalence of MPS IV by 5-yr age cohort, males (000s)
Table 64. China prevalence of MPS IV by 5-yr age cohort, females (000s)
Table 65. South Korea prevalence of MPS IV by 5-yr age cohort, males (000s)
Table 66. South Korea prevalence of MPS IV by 5-yr age cohort, females (000s)
Table 67. India prevalence of MPS IV by 5-yr age cohort, males (000s)
Table 68. India prevalence of MPS IV by 5-yr age cohort, females (000s)
Table 69. Australia prevalence of MPS IV by 5-yr age cohort, males (000s)
Table 70. Australia prevalence of MPS IV by 5-yr age cohort, females (000s)
Table 71. Brazil prevalence of MPS IV by 5-yr age cohort, males (000s)
Table 72. Brazil prevalence of MPS IV by 5-yr age cohort, females (000s)
Table 73. Mexico prevalence of MPS IV by 5-yr age cohort, males (000s)
Table 74. Mexico prevalence of MPS IV by 5-yr age cohort, females (000s)
Table 75. Argentina prevalence of MPS IV by 5-yr age cohort, males (000s)
Table 76. Argentina prevalence of MPS IV by 5-yr age cohort, females (000s)